Sanchi-Iko Pharmaceutical

Nichi-Iko Pharmaceutical is a leading Japanese generic pharmaceutical company specializing in the development, manufacturing, and distribution of high-quality generic drugs and biosimilars. Founded in 1965 and headquartered in Toyama, Japan, the company has established itself as a dominant player in the domestic market and has expanded globally through strategic acquisitions, most notably Sagent Pharmaceuticals in the United States. Its extensive product portfolio covers a wide range of therapeutic areas, including circulatory, digestive, respiratory, and central nervous system treatments. Nichi-Iko is particularly focused on the biosimilars market, leveraging its advanced manufacturing infrastructure to provide cost-effective alternatives for complex biologic therapies. The company operates multiple GMP-certified manufacturing facilities across Japan and maintains a robust pipeline of injectable and oral medications.